Full Press Release Details
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023.
IMMP
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
Key Takeaway: Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
Price reaction · baseline $2.03 (2023-10-23 close) · hit after-hours · 3 other IMMP headline(s) in the window, move may be shared
day 0 close
-7.4%
day 1
-4.9%
day 3 · peak
-7.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)